Breaking News Instant updates and real-time market news.

BLRX

BioLineRx

$0.98

-0.22 (-18.33%)

, MRK

Merck

$72.34

0.12 (0.17%)

13:27
10/21/18
10/21
13:27
10/21/18
13:27

BioLineRx discloses additional data from Phase 2a COMBAT/KEYNOTE-202 study

BioLineRx (BLRX) disclosed additional data from the in-depth analyses of biopsies of the dual combination arm of the Phase 2a COMBAT/KEYNOTE-202 study, evaluating patients with metastatic pancreatic adenocarcinoma treated with BL-8040 in combination with Keytruda, an anti-PD-1 therapy marketed by Merck (MRK). The results presented demonstrate that BL-8040 significantly improves T-cell infiltration into the tumor and reduces immunosuppression in the tumor microenvironment. The study included 37 patients with metastatic PDAC who had disease progression after one or more previous lines of treatment. Study treatment consisted of an initial 5-day priming period of BL-8040 monotherapy, followed by repeated 3-week cycles of BL-8040 in combination with Keytruda. In addition to clinical efficacy assessments, the study included a number of pharmacodynamic assessments to support BL-8040's mechanism of action as an immuno-oncology agent. The additional data from in-depth analyses of biopsies taken at screening and following monotherapy or combination treatment of BL-8040 and Keytruda demonstrate that in 75% of the available biopsies, BL-8040 treatment promotes an increase in the number of infiltrating CD4+, CD8+ and CD8+Granzyme B+ cytotoxic T-cells. The greatest improvement in T-cell infiltration was observed following combination treatment of BL-8040 and Keytruda and was correlated with stable disease for 8 cycles of treatment. Furthermore, increased infiltration of activated CD4 and CD8 T-cells was accompanied by a pronounced decrease in the number of tumor cells, as well as by a decrease in myeloid-derived suppressor cells, a cell type known to impede the anti-tumor immune response.

BLRX

BioLineRx

$0.98

-0.22 (-18.33%)

MRK

Merck

$72.34

0.12 (0.17%)

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 11

    Jan

  • 16

    Feb

BLRX BioLineRx
$0.98

-0.22 (-18.33%)

10/03/18
HCWC
10/03/18
NO CHANGE
Target $4
HCWC
Buy
H.C. Wainwright positive on BioLineRx economic stake increase in BL-8040
H.C. Wainwright analyst Joseph Pantginis notes that BioLineRx (BLRX) announced the increase of its economic stake in BL-8040 from 60% to 80% from Biokine Therapeutics. The analyst believes that this transaction should signal increased confidence to investors as to the company's increased investment into BL-8040. Additionally, Pantginis argues that COMBAT data at ESMO later this month represents a potential tipping point for shares. COMBAT is a Phase 2a open-label study evaluating the safety and efficacy of BL-8040 in combination with pembrolizumab in patients with advanced pancreatic cancer in collaboration with Merck (MRK). He reiterates a Buy rating and $4 price target on BioLineRx shares.
03/06/18
HCWC
03/06/18
NO CHANGE
HCWC
H.C. Wainwright sees several second half data catalysts for BioLineRx
H.C. Wainwright analyst Joseph Pantginis noted that BioLineRx's Q4 and FY17 financial results missed the firm's estimates slightly, but he was optimistic about the company's second half data catalysts -- including topline results from COMBAT, lead-in stage results for the Phase 3 GENESIS study, partial results from Phase 1b/2 studies for BL-8040 in combination with Tecentriq in gastric cancer, NSCLC, and AML, as well as data from multiple other studies. Pantginis reiterated a Buy rating and has a $4 price target on BioLineRx shares.
MRK Merck
$72.34

0.12 (0.17%)

10/16/18
WELS
10/16/18
NO CHANGE
WELS
Drug price in ads not impactful, may cause confusion, says Wells Fargo
Wells Fargo analyst David Maris acknowledges that the U.S. Department of Health and Human Services' proposal to include drug prices in advertisements has a "noble goal" of making drugs more affordable and keeping patients well informed. However, given how different list prices are relative to out of pocket costs, "one must ask if this is increasing transparency or likely going to lead to more confusion," he contends. The analyst also believes that the unintended consequence could be worse care, while noting that the drug price information will likely fall into the category of the side effect information in drug ads currently, tuned out by many and will have no material impact. While he supports the idea of increased transparency, Maris wonders whether the potential benefit is not outweighed by the potential negative for the most vulnerable. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
10/16/18
SBSH
10/16/18
NO CHANGE
Target $79
SBSH
Buy
Merck price target raised to $79 from $70 at Citi
Citi analyst Andrew Baum raised his price target for Merck (MRK) to $79 and reiterates a Buy rating on the shares. Following upward revisions to his Lynparza expectations, the analyst raised his earnings forecasts for Merck by 1%-9% over the 2021 to 2025 timeframe. The analyst anticipates that positive Lynparza first-line ovarian cancer trial will make Lynparza standard of care in wild type first-line ovarian cancer patients and leaving it well positioned to take market share in immuno-oncology based combinations post 2021. Baum also raised his price target for AstraZeneca (AZN), Merck's partner on Lynparza, to GBP 70 from GBP 62. He also has a Buy rating on those shares.
10/16/18
BTIG
10/16/18
INITIATION
Target $82
BTIG
Buy
Esperion initiated with a Buy at BTIG
BTIG analyst Thomas Shrader initiated Esperion (ESPR) with a Buy rating and a price target of $82, saying that with its development of bempedoic acid, or BA, to reduce cholesterol, the next key question is about the drug's safety. The analyst notes that while the data from Study 1 in May were disappointing, Study 2 readout in the next few weeks should have more answers. Shrader adds that the introduction of "non-stain" into the cholesterol market has already worked for Merck's (MRK) Zetia, and if BA is perceived well on its safety profile, it is "highly supportive" of its investment story.
10/11/18
FBCO
10/11/18
NO CHANGE
Target $81
FBCO
Outperform
Merck price target raised to $81 from $71 at Credit Suisse
Credit Suisse analyst Vamil Divan raised his price target for Merck to $81 from $71, while reiterating an Outperform rating on the shares. While the shares have had a significant move this year, the analyst sees room for additional upside as the company continues to roll out Keytruda, most notably in the 1st line non-small cell lung setting. However, Divan also acknowledges longer-term investors remain concerned about how the company will navigate the Januvia patent expiration in mid-2022.

TODAY'S FREE FLY STORIES

SEAS

SeaWorld

$30.09

-0.01 (-0.03%)

16:17
09/16/19
09/16
16:17
09/16/19
16:17
Hot Stocks
SeaWorld CEO Gustavo Antorcha resigns, Marc Swanson named interim CEO »

SeaWorld announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
09/16/19
09/16
16:17
09/16/19
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
09/16/19
09/16
16:16
09/16/19
16:16
Technical Analysis
NYSE market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADUS

Addus HomeCare

$77.36

-0.74 (-0.95%)

16:16
09/16/19
09/16
16:16
09/16/19
16:16
Conference/Events
Addus HomeCare management to meet with Jefferies »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 13

    Nov

TNXP

Tonix Pharmaceuticals

$0.49

0.0136 (2.89%)

16:15
09/16/19
09/16
16:15
09/16/19
16:15
Hot Stocks
Tonix Pharmaceuticals announces licensing pact with Columbia University »

Tonix Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Sep

  • 25

    Sep

XOM

Exxon Mobil

$73.76

1.13 (1.56%)

, CVX

Chevron

$124.13

2.67 (2.20%)

16:14
09/16/19
09/16
16:14
09/16/19
16:14
On The Fly
Fly Intel: Wall Street's top stories for Monday »

Stocks were lower, and…

XOM

Exxon Mobil

$73.76

1.13 (1.56%)

CVX

Chevron

$124.13

2.67 (2.20%)

WLL

Whiting Petroleum

$11.23

3.7 (49.14%)

DNR

Denbury Resources

$1.56

0.35 (28.93%)

XOG

Extraction Oil & Gas

$4.17

0.95 (29.50%)

CDEV

Centennial Resource Development

$5.80

1.39 (31.52%)

GM

General Motors

$37.19

-1.64 (-4.22%)

NXST

Nexstar

$107.16

5.03 (4.93%)

TRCO

Tribune Media

$46.65

0.03 (0.06%)

BX

Blackstone

$53.51

-0.04 (-0.07%)

MGM

MGM Resorts

$29.69

0.65 (2.24%)

CNHI

CNH Industrial

$11.17

-0.03 (-0.27%)

ALDR

Alder Biopharmaceuticals

$18.68

8.63 (85.87%)

SEMG

SemGroup

$16.50

6.22 (60.51%)

ET

Energy Transfer LP

$13.41

-0.6 (-4.28%)

NEWR

New Relic

$58.44

0.1 (0.17%)

MNK

Mallinckrodt

$3.01

-0.29 (-8.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 23

    Sep

  • 26

    Sep

  • 26

    Sep

  • 08

    Oct

  • 09

    Oct

  • 21

    Oct

  • 07

    Nov

  • 13

    Nov

  • 21

    Feb

APA

Apache

$28.46

4.13 (16.97%)

16:14
09/16/19
09/16
16:14
09/16/19
16:14
Initiation
Apache initiated  »

Apache initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

  • 13

    Nov

ALDR

Alder Biopharmaceuticals

$18.59

8.54 (84.98%)

16:13
09/16/19
09/16
16:13
09/16/19
16:13
Downgrade
Alder Biopharmaceuticals rating change  »

Alder Biopharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 21

    Oct

  • 21

    Feb

CME

CME Group

$207.10

1.35 (0.66%)

16:13
09/16/19
09/16
16:13
09/16/19
16:13
Initiation
CME Group initiated  »

CME Group initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ICE

IntercontinentalExchange

$91.87

1.04 (1.15%)

16:13
09/16/19
09/16
16:13
09/16/19
16:13
Initiation
IntercontinentalExchange initiated  »

IntercontinentalExchange…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

NDAQ

Nasdaq

$99.21

-0.3 (-0.30%)

16:12
09/16/19
09/16
16:12
09/16/19
16:12
Initiation
Nasdaq initiated  »

Nasdaq initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

CBOE

Cboe Global Markets

$111.07

0.21 (0.19%)

16:11
09/16/19
09/16
16:11
09/16/19
16:11
Initiation
Cboe Global Markets initiated  »

Cboe Global Markets…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBCP

Concrete Pumping

$4.33

0.195 (4.72%)

16:10
09/16/19
09/16
16:10
09/16/19
16:10
Earnings
Concrete Pumping sees FY19 revenue $284M, consensus 292.54M »

The company now expects…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Sep

BBCP

Concrete Pumping

$4.33

0.195 (4.72%)

16:07
09/16/19
09/16
16:07
09/16/19
16:07
Earnings
Concrete Pumping reports Q3 EPS 5c, consensus 7c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Sep

MRVL

Marvell

$25.42

-0.43 (-1.66%)

16:07
09/16/19
09/16
16:07
09/16/19
16:07
Hot Stocks
Marvell's Gaynor sells 35,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EAST

Eastside Distilling

$4.99

-0.01 (-0.20%)

16:07
09/16/19
09/16
16:07
09/16/19
16:07
Hot Stocks
Eastside Distilling acquires Azunia Tequila in all-stock transaction »

Eastside Distilling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LNG

Cheniere Energy

$65.71

0.21 (0.32%)

, EOG

EOG Resources

$85.61

6.24 (7.86%)

16:06
09/16/19
09/16
16:06
09/16/19
16:06
Hot Stocks
Cheniere Energy, EOG Resources announce gas supply agreements »

Cheniere Energy (LNG)…

LNG

Cheniere Energy

$65.71

0.21 (0.32%)

EOG

EOG Resources

$85.61

6.24 (7.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UFPI

Universal Forest

$40.47

-0.66 (-1.60%)

16:06
09/16/19
09/16
16:06
09/16/19
16:06
Hot Stocks
Universal Forest acquires Pallet USA »

Universal Forest Products…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

BJ

BJ's Wholesale

$26.81

-0.64 (-2.33%)

16:05
09/16/19
09/16
16:05
09/16/19
16:05
Hot Stocks
BJ's Wholesale names Lee Delaney president »

BJ's Wholesale Club…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

PSTV

Plus Therapeutics

$9.50

-0.06 (-0.63%)

16:05
09/16/19
09/16
16:05
09/16/19
16:05
Syndicate
Breaking Syndicate news story on Plus Therapeutics »

Plus Therapeutics files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACRS

Aclaris Therapeutics

$1.10

0.065 (6.31%)

16:00
09/16/19
09/16
16:00
09/16/19
16:00
Hot Stocks
Breaking Hot Stocks news story on Aclaris Therapeutics »

Aclaris Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ETN

Eaton

$86.32

-1.15 (-1.31%)

15:54
09/16/19
09/16
15:54
09/16/19
15:54
Hot Stocks
Eaton's Semeslberger sells 17,000 ordinary shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRS

Carpenter Technology

$55.59

0.45 (0.82%)

15:51
09/16/19
09/16
15:51
09/16/19
15:51
Hot Stocks
Carpenter Technology director Steven Karol sells $275K in company shares »

Carpenter Technology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,806.42

-31.07 (-1.69%)

15:51
09/16/19
09/16
15:51
09/16/19
15:51
Hot Stocks
Amazon says WSJ search results story is wrong »

In response to a Wall…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

MUR

Murphy Oil

$25.21

4.62 (22.44%)

15:45
09/16/19
09/16
15:45
09/16/19
15:45
Options
Murphy Oil call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.